Bob Cormier

They cover biomanufacturing of biologics, medical devices such as implantables, instruments and precision components, and pharmaceuticals, later widening the list to contract and device manufacturing, diagnostics, distribution, research institutions and clinical care.

• The range runs from a startup filling its first small batch to contract manufacturers and OEMs running high volumes.
• The jobs, they stress, aren't only for PhDs: they include machinists and quality technicians, regulatory and supply chain specialists, engineers, sales teams and clinicians.
• Cormier argues that companies can both invent and manufacture in Rhode Island, an uncommon combination.

"Our largest life-science companies are manufacturers...

• Not satellite sales offices.
• Plants.
• Places where product gets made," Cormier writes, listing biomanufacturing, medical devices and pharma as the three categories.
• They frame the usual choice as where to invent and develop or where to manufacture, and say Rhode Island breaks that tradeoff.

Cormier describes a change in their understanding, not a change of position: "What I didn't fully appreciate is that our life-science industry is a manufacturing industry."

Read original · Original 2 · Original 3

Life sciences accounts for 5,259 jobs, or 1.1% of Rhode Island's 499,281.

• They place that slice within the three sectors it sits in — manufacturing, professional and technical services, and health care — rather than treating it as a standalone industry.
• The addressable workforce, they argue, is regional: the labor pool within a 45-minute drive of the state nearly doubles it, and more than 82,000 Rhode Islanders already commute out of state.
• Cormier says they were one of those commuters for years.

Cormier presents the 1.1% share "as the sliver it is," sets it within the sectors it belongs to and asks how large the actual pool is. They conclude that the state's size benefits companies and people in Rhode Island and nearby.

Read original · Original 2 · Original 3

Recent awards — $26 million from NIH for Advance Rhode Island Clinical & Translational Research, $37 million from the Starr Foundation for an alliance at Brown University and Brown University Health, and $100 million from Organogenesis for a regenerative-medicine manufacturing facility in Smithfield with 100-plus jobs — sit alongside commitments dating to 2018, including Amgen's $160 million West Greenwich plant and the $88 million Wexford Innovation Center.

• They total more than $1 billion invested in the ecosystem and $2.7 billion in NIH research grants won by Rhode Island scientists from 2016 to 2025, up about 60% over the decade, citing NIH RePORTER as the source for the grant figures.
• Cormier's point: repeat funding over a decade is not luck; the total reflects momentum, not a moment.

Sector employment grew 24.5% between 2019 and 2023, against 14.7% nationally.

• Another 634,000 square feet of lab and research space is coming online through 2027, including Brown's Danoff Laboratories, described as the state's largest academic lab building.
• Cormier also measures progress against the state's past: two declining manufacturing codes in the sector shed 453 jobs over the last decade, and the state has committed back more than three-quarters of that in under two years.

Read original · Original 2

Attraction and retention are not competing strategies; every state Rhode Island competes with uses incentives; and existing employers are the most likely to expand next.

• The business climate for incumbents, they argue, deserves as much attention as recruitment.
• Cormier calls this a fair debate worth having but declines to rank which industries matter most, saying it is not their place — a limit on the claim, not a hedge on the argument.

Writing off a Nabsys announcement that widened into a debate about state investment, Cormier argues the story "shouldn't rest on any single company, but on the whole of what life sciences in Rhode Island actually is," and asks that companies already here be treated with the same seriousness as ones being recruited.

Read original

Unlocking future healthcare, they argue, takes more than any single company, hospital or university: it requires partnerships between industry and academic medicine, manufacturers and clinicians, and the people who discover something and those who can build it at scale. A small state makes those partnerships easier to convene than a larger market, Cormier says, and the work is generational.

"Rhode Island is small enough that those partnerships are easier to convene here than in a larger market.

• That's an advantage, not a consolation."
• Cormier closes the investment argument with the same framing: "We're early.
• We're not unproven."

Read original · Original 2

They point to six years of pandemic, supply-chain breakdowns and tariffs, and distill the argument into one contrast: suppliers send you a notice; partners pick up the phone.

• Small changes made together can turn a weak spot into a competitive edge.
• Many Rhode Island companies, Cormier notes, already have global trade ties, partners, customers and operations to build on.

Cormier delivered the lunch keynote at Bryant University's 40th Annual Global Trade Summit on September 24, drawing on experience rather than theory.

• The post announcing the talk carries the summit hashtags and names the John H.
• Chafee Center for International Business.

Read original

They make a place-based case: the companies that figure out that convergence win the next decade, and the places that host the conversation win with them. Rhode Island, Cormier says, wants to be one of those places.

Cormier connects the theme to Fountainhead RI's AI and Infrastructure Summit, Part Two, in Providence on October 23.

• Framed as "How Organizations Compete, Build, and Win in the AI Era," it features a keynote, fireside chats, expert panels, a hackathon, a technology showcase and a VIP dinner the night before.
• The pitch to companies: spend the day with the room.

Read original

It states the idea Cormier returns to across the other posts — that Rhode Island is a life-science manufacturing state, not just a research address — and shows their plain, first-person way of explaining it, with no jargon to decode.

Cormier says Rhode Island is home to nearly 100 life-science companies and argues the state breaks the usual choice between a place to invent and a place to manufacture.

• They divide the sector into biomanufacturing (biologics grown at scale under tight tolerances), medical devices (implantables, instruments and precision components made for other companies' products) and pharma.
• The range, they note, spans a startup's first small batch to contract manufacturers and OEMs running high volumes.
• They add that the labor market within commuting distance is several times the state's own population, then tease the next post's explanation of why almost nobody outside Rhode Island knows any of this.

For brands planning a campaign

For a site-selection brief, this is the quickest way to judge whether Cormier can speak to a state's manufacturing depth, not just its research base. It supports a panel or advisory ask on doing development and production in one place.

Cormier reports that life sciences accounts for 1.1% of Rhode Island's 499,281 jobs, or 5,259 people, across three sectors: manufacturing, professional and technical services, and health care.

• The larger claim is geographic: the workforce within a 45-minute drive of the state nearly doubles the labor pool, and more than 82,000 Rhode Islanders already commute out of state — Cormier notes having been one of them for years.
• The post says the data sources are noted on an attached graphic drawn from public sources.
• Ask for the graphic and underlying tables.

For brands planning a campaign

This gives a defensible answer to hiring-capacity questions and a natural opening for Cormier as a speaker or advisor on regional workforce. Ask for the attached chart; the numbers rest on it.

Read it to see whether the momentum claim holds up when itemized.

Cormier opens by conceding the recent numbers look modest next to Boston or the Bay Area, then itemizes the past year: $26 million from NIH for Advance Rhode Island Clinical & Translational Research, a third award in a decade; $37 million from the Starr Foundation for the Starr Healthspan Innovation Alliance at Brown University and Brown University Health; $100 million from Organogenesis for a regenerative-medicine manufacturing facility in Smithfield with 100-plus jobs, from a Massachusetts company that chose Rhode Island.

• They add Ocean State Labs, described as the state's first life-science incubator, the new state health lab at 150 Richmond, and Brown's Danoff Laboratories, opening in the spring.
• The longer ledger runs 2018 to 2024: Amgen's West Greenwich biomanufacturing plant at $160 million, $100 million for Brown's Carney Institute for Brain Science, the Wexford Innovation Center at $88 million, $24 million for URI's Ryan Institute for Neuroscience, $25 million for Brown's Legorreta Cancer Center, $92 million for the state health lab and Ocean State Labs, $45 million for the Rhode Island Life Science Hub, $150 million from Brown University to Brown University Health over seven years, and $87.5 million for URI's Biomedical Sciences Building approved by voters.
• Cormier totals more than $1 billion invested in the ecosystem and $2.7 billion in NIH research grants won by Rhode Island scientists from 2016 to 2025, up 60% over the decade, with more than half of it in the last five years.
• The post cites NIH RePORTER, awards to Rhode Island organizations, FY2016-2025.

For brands planning a campaign

The piece to cite when a client asks whether the state's momentum is real. It also shows that Cormier discloses a source and date range rather than simply asserting a trend.

Cormier reports that life-science employment grew 24.5% between 2019 and 2023 against 14.7% nationally, and that 634,000 square feet of lab and research space is coming online through 2027.

• They point to 150 Richmond Street, which opened last October, with Ocean State Labs inside from May, and Brown's Danoff Laboratories — 300,000 square feet, described as the largest academic lab building in the state — opening next year.
• Organogenesis moved capacity from Canton, Massachusetts, to Smithfield, and Nabsys is building a new headquarters in Providence.
• Cormier closes with a comparison to the state's own past: two declining manufacturing codes in the sector shed 453 jobs across the last decade, and the state has committed back more than three-quarters of that in under two years.

For brands planning a campaign

Useful for assessing whether growth is real or promotional: it compares the state to a national baseline and to its own prior decade of losses.

Read it to see whether they take positions or only compile data.

Responding to an announcement that widened into a debate about how the state invests in growth, Cormier argues the story should not rest on any single company but on what life sciences in Rhode Island actually is.

• They describe a sector encompassing contract and device manufacturing, diagnostics, distribution, research institutions and clinical care, from companies of real scale to companies of six people, from Pawtucket to East Greenwich.
• The jobs, they write, are not only for PhDs: machinists and quality technicians, regulatory and supply chain specialists, engineers, sales teams and clinicians.
• They argue that nearly all the debate is about attracting companies, with far less attention to those already there.
• Attraction and retention are not competing strategies; every state they compete with uses incentives, and the conditions a state creates decide whether existing employers grow, stay or look elsewhere.
• They call the work generational and built on partnerships between industry and academic medicine, and note that a small state makes those partnerships easier to convene.

For brands planning a campaign

If the engagement includes ecosystem or policy advice, this post shows Cormier takes a position — on retention and business climate — rather than staying neutral.

Cormier announces a lunch keynote at Bryant University's 40th Annual Global Trade Summit on September 24.

• The working idea: a supply chain moves goods, while a value chain is built on relationships, which start with respect — taking time to understand local needs and customs is how a supplier becomes a partner.
• They point to the last six years of pandemic, supply-chain breakdowns and tariffs, and sum up the contrast in one line: suppliers send you a notice, partners pick up the phone.
• They add that small, joint changes can turn a weak spot into a competitive edge, and that many Rhode Island companies already have global trade ties to build on.

For brands planning a campaign

A ready-made speaker angle for events on trade, supply chain or manufacturing partnerships, and the clearest evidence that Cormier's range extends beyond in-state statistics. The post's dates are event dates, not publication dates.

One post cites employment growth of 24.5% between 2019 and 2023, against 14.7% nationally.

• Another puts life sciences at 5,259 jobs, or 1.1% of Rhode Island's 499,281 total jobs, and shows the sector spanning manufacturing, professional and technical services, and health care.
• The recurring point: the addressable workforce extends beyond the state.
• The labor pool within a 45-minute drive of Rhode Island nearly doubles, and roughly 82,000 Rhode Islanders already commute out of state.

Builds each post around a chart or dataset, names the public sources behind the numbers, and pairs a state figure with a national or regional comparison.

For brands planning a campaign

Useful for a site-selection or economic-development brief that needs someone who can speak to workforce availability and commuting patterns, not just headline job counts.

Examples: Source 1 · Source 2 · Source 3

One post stacks recent awards ($26 million from NIH for Advance Rhode Island Clinical & Translational Research, $37 million from the Starr Foundation at Brown, and $100 million from Organogenesis in Smithfield) on top of earlier commitments, including the 2018 Amgen biomanufacturing plant at $160 million and the 2019 Wexford Innovation Center at $88 million.

• The totals they present are more than $1 billion invested in the ecosystem and nearly $3 billion in NIH research grants won by Rhode Island scientists between 2016 and 2025, up about 60% over the decade.
• They cite NIH RePORTER as the source for the grant figures.

Uses a dated list format, separates ecosystem investment from research funding, and presents funding as evidence of momentum rather than a one-off.

For brands planning a campaign

A concrete starting point for a funder, university, or economic-development client seeking a speaker or advisor who can frame Rhode Island's investment case with figures and sources.

Examples: Source 1

Cormier describes nearly 100 life-science companies spanning research, manufacturing, and distribution, and says the state's largest life-science employers are manufacturers with plants, not satellite sales offices.

• They cover biomanufacturing of biologics; medical devices, including implantables, instruments, and precision components; and pharmaceuticals.
• A related post widens the definition to contract and device manufacturing, diagnostics, distribution, research institutions, and clinical care, emphasizing that these jobs aren't only for PhDs.
• Cormier's framing is that a company can both invent and manufacture in Rhode Island, an uncommon combination.

Defines the sector by listing its sub-industries and company types, then contrasts them with the narrower assumptions readers may bring.

For brands planning a campaign

Relevant to a client deciding whether Rhode Island can support both development and production, or to a brief that needs an advisor comfortable discussing manufacturing operations and supply roles.

Examples: Source 1 · Source 2 · Source 3

They say attraction and retention aren't competing strategies, and that existing employers are most likely to expand next; the business climate for incumbents therefore deserves the same attention as recruitment incentives. Cormier presents this as a fair debate and declines to rank which industries matter most.

Opens with a specific news event, steps back to the policy question, and distinguishes the claims Cormier makes from the ones they say aren't theirs to settle.

Cormier says it isn't their place to decide which industries matter most, so the post argues for a process view rather than ranking sectors.

For brands planning a campaign

Suited to a policy, chamber, or economic-development brief seeking a speaker who can make the case for retention without attacking recruitment incentives.

Examples: Source 1

Cormier ties that theme to a Providence event: Fountainhead RI's AI and Infrastructure Summit, Part Two, on October 23, framed as "How Organizations Compete, Build, and Win in the AI Era," with a keynote, fireside chats, expert panels, a hackathon, a technology showcase, and a VIP dinner the night before.

Connects a sector trend to a specific convening and describes the event format in enough detail for readers to judge whether to attend.

For brands planning a campaign

Useful for a technology or life sciences client seeking a speaker or panel participant who can bridge AI adoption and bioscience applications in a regional market.

Examples: Source 1

They illustrate the argument with the past six years of disruption: a pandemic, supply-chain breakdowns, and tariffs.

• Their line is that suppliers send a notice while partners pick up the phone, and that small changes made together can turn a weak spot into a competitive edge.
• Cormier notes that many Rhode Island companies already have global trade ties to build on.

Builds the talk around a plain-language distinction, then grounds it in recent disruption rather than abstract trade theory.

For brands planning a campaign

Relevant to an international business, trade, or manufacturing client seeking a speaker who can make cross-border partnerships practical for a regional company audience.

Examples: Source 1

Supporting points include a regional labor pool that nearly doubles within a 45-minute drive, the ability to convene industry and academic partners more easily than in a larger market, and the concentration of life-science manufacturers in a compact area. They frame the state’s small size as something to be honest about and a reason it can move faster on partnerships.

Concedes the obvious objection in the first line, then answers it with a specific number or structural advantage.

For brands planning a campaign

A useful angle for a regional client seeking an advocate who can address the size objection directly.

Examples: Source 1 · Source 2 · Source 3

Chafee Center for International Business. The post announces the speaking role and links to registration.

View example

View example

Vercauteren works inside a health system, describing its youth career exploration programs, apprenticeships and partnerships with high schools, community colleges and workforce boards, while trading notes with peers at other systems. Cormier works from public labor and investment data on an entire state, argues for incentives and retention policy, and presents workforce size as an economic-development selling point rather than a program to run.

Read original · Original 2

Both also use posts for brief commentary on developments rather than long essays.

Lewis covers the global pharmaceutical industry through roundups of deals, regulation, layoffs and trial results, often naming companies from several countries in a single post. Cormier focuses on one state's ecosystem, using public datasets and dated investment totals rather than breaking news to draw conclusions about policy and place.

Read original · Original 2

Both also write from inside the room where those decisions are discussed.

Hemlani writes about a national build-out in the UAE, where sovereign wealth, a new regulator, genomics sequencing and manufacturing campuses sit under one owner, and contrasts that model with fragmented Western biotech. Cormier writes about an existing American state with manufacturers that must compete for attention against larger markets; Hemlani's posts have no equivalent to the trade and relationship framing in Cormier's global-trade talk.

Read original · Original 2

The two posts show how healthcare career pathways are built in practice: through youth career-exploration programs and partnerships with high schools, community colleges, universities, workforce boards and community organizations, and through apprenticeship programs at another health system to train the next generation of workers.

• For a consultancy advising a hospital, workforce board or regional talent initiative on how pipelines are assembled, those operational details about named partners and shortages sit closer to the decision than a state investment ledger.
• Both posts also show the person presenting in roundtable and conference settings, making them a direct fit for a speaker engagement.

The posts cover healthcare workforce development inside Massachusetts health systems, not Rhode Island’s life-sciences labor pool, capital investment or laboratory pipeline.

• A site-selection client would still need Cormier’s quantitative layer — the 5,259 life-sciences jobs, the labor pool that nearly doubles within a 45-minute drive, the 634,000 square feet of lab space coming online and the 2018–2024 investment ledger — which is absent here.
• Vercauteren writes about programs and events rather than state-level economics, so the two cover different halves of the same site-selection need; neither substitutes for the other.

Examples: Source 1 · Source 2

One post is a broad industry scan covering licensing deals, FDA leadership turnover, layoffs, top-selling drugs, EU supply-security rules, AI drug-design funding and a gene-therapy trial readout.

• The other explains why automation and digital manufacturing now touch every stage of a facility lifecycle — design, project execution, CQV, start-up, operational readiness and ongoing operations — and argues that complex manufacturing problems are rarely solved by optimizing one discipline in isolation.
• For a consultancy advising a client weighing whether a region can support advanced biomanufacturing, that lifecycle and integration view adds the substantive layer Cormier’s posts lack.

The material is a national and global industry digest plus a corporate integration note, not regional analysis.

• It contains no Rhode Island workforce figures, state incentive or retention argument, or labor-pool evidence a site selector can act on.
• The scan lists deals and regulatory changes without tying them to a location decision.
• Choosing this instead of Cormier means trading a specific, sourced regional case for breadth and supplying the place-based analysis from elsewhere.

Examples: Source 1 · Source 2

The two posts make a structural argument: most biotech systems are fragmented across countries and institutions, while the UAE is attempting to bring capital, regulation, manufacturing and genomic data under one roof.

• They cite Mubadala’s biotech holdings, a new longevity authority chaired at crown-prince level, a national manufacturing drive and a population-scale genomics program.
• A second post frames the same case through the gap between the UAE’s two billion dollars of venture capital and its 2.5 trillion dollars of sovereign wealth, and the split between Dubai and Abu Dhabi as funding markets.
• For a consultancy advising a national or sovereign client on ecosystem strategy, that framing maps onto the decision.

The posts are entirely about the UAE.

• They address neither Rhode Island nor the US Northeast or the commuting labor pool a site selector needs; the implied audience is founders and investors raising or deploying capital rather than people comparing states.
• They also name colleagues and a hosted breakfast rather than present published workforce evidence.
• Choosing these posts means trading Cormier’s usable regional dataset for a different geography; applying them to a Rhode Island or US regional site-selection comparison would require new research.

Examples: Source 1 · Source 2